Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19228005 | ANALYSIS OF A POLYNUCLEOTIDE VIA A NANOPORE SYSTEM | June 2025 | October 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18986602 | ESTIMATING TUMOR PURITY FROM SINGLE SAMPLES | December 2024 | August 2025 | Allow | 8 | 1 | 1 | No | No |
| 18885331 | DETECTION OF METHYLATION STATUS OF A DNA SAMPLE | September 2024 | May 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18673376 | METHOD FOR SCREENING LACTOBACILLUS CASEI FERMENTATION AGENT | May 2024 | October 2024 | Allow | 5 | 1 | 0 | No | No |
| 18576506 | METHOD FOR COLD PLASMA INDUCED CELL DEATH IN BREAST CANCER CELLS BY 8-OXOG MODIFICATION AND DEGRADATION OF HISTONE MRNA | January 2024 | May 2025 | Allow | 16 | 2 | 0 | No | No |
| 18330279 | METHODS FOR ASSEMBLING AND READING NUCLEIC ACID SEQUENCES FROM MIXED POPULATIONS | June 2023 | October 2024 | Abandon | 16 | 2 | 0 | No | No |
| 18122246 | Methods for Characterization of Viral Genome Using Base Modifications | March 2023 | February 2026 | Allow | 35 | 1 | 0 | No | No |
| 18115405 | METHODS FOR SEPARATING AND DETECTING DOUBLE-STRANDED AND SINGLE-STRANDED RIBONUCLEIC ACID (RNA) | February 2023 | February 2026 | Allow | 36 | 1 | 0 | No | No |
| 18173060 | SPECIFIC DNA FRAGMENT OF FEMALE ACIPENSER DABRYANUS AND METHOD FOR IDENTIFYING THE SEX OF ACIPENSER DABRYANUS | February 2023 | May 2024 | Allow | 27 | 2 | 0 | No | No |
| 18064892 | Multiplex Q-PCR Arrays | December 2022 | September 2025 | Abandon | 33 | 1 | 0 | No | No |
| 18076214 | RNA SEQUENCING METHODS | December 2022 | September 2025 | Allow | 33 | 0 | 0 | No | No |
| 18073515 | METHOD AND APPARATUS FOR THE ANALYSIS AND IDENTIFICATION OF MOLECULES | December 2022 | March 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17992668 | METHODS OF DETECING LUNG CANCER | November 2022 | September 2025 | Allow | 34 | 1 | 0 | No | No |
| 18052811 | L-RNA APTAMERS AND METHODS OF IDENTIFYING THE SAME | November 2022 | January 2026 | Allow | 38 | 1 | 0 | No | No |
| 18045369 | FAST AND ROBUST BI-FUNCTIONAL MUTANTS OF TAQ DNA POLYMERASE | October 2022 | February 2026 | Allow | 40 | 1 | 0 | No | No |
| 17916140 | METHOD OF DETECTING AN ANALYTE IN A MEDIUM COMPRISING A LIGHT SCATTERING CONSTITUENT | September 2022 | February 2026 | Allow | 40 | 1 | 0 | No | No |
| 17915832 | PRIMER SET AND PROBE FOR DETECTING STAPHYLOCOCCUS ARGENTEUS | September 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17933442 | Multiplex Q-PCR Arrays | September 2022 | August 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17932895 | SPATIAL-DEPENDENT ANALYSIS OF BIOLOGICAL MATERIAL FROM INTACT TISSUE SAMPLES | September 2022 | February 2026 | Allow | 41 | 1 | 0 | No | No |
| 17293412 | ELECTRONIC DETECTION OF NUCLEIC ACID STRUCTURE | September 2022 | July 2025 | Allow | 50 | 1 | 0 | No | No |
| 17905659 | Viral multimeric peptide constructs for targeting PDZ domains | September 2022 | February 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17758828 | HIGH THROUGHPUT GENETIC BARCODING AND ANALYSIS METHODS | July 2022 | December 2025 | Allow | 41 | 1 | 0 | No | No |
| 17864913 | LABELING STRATEGY FOR USE IN DNA SEQUENCING TO FACILITATE ASSEMBLY OF SEQUENCE READS INTO LONGER FRAGMENTS OF A GENOME | July 2022 | May 2025 | Allow | 34 | 1 | 0 | No | No |
| 17863110 | METHODS AND DEVICES FOR MEASURING DUPLEX UNWINDING OR STRAND EXCHANGE EFFICIENCY | July 2022 | March 2026 | Allow | 44 | 2 | 0 | No | No |
| 17855325 | FLOW CELLS | June 2022 | September 2025 | Allow | 39 | 1 | 0 | No | No |
| 17852737 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISEASES, METHODS OF DETECTION AND USES THEREOF | June 2022 | September 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17847210 | SEX IDENTIFICATION SPECIFIC DNA SEQUENCE AND SEX IDENTIFICATION METHOD OF CHINESE MITTEN CRAB ERIOCHEIR SINENSIS | June 2022 | September 2025 | Allow | 39 | 2 | 0 | No | No |
| 17757861 | SIMPLIFIED POLYNUCLEOTIDE SEQUENCE DETECTION METHOD | June 2022 | December 2025 | Allow | 42 | 2 | 0 | No | No |
| 17835439 | DIGITAL ANALYTE ANALYSIS | June 2022 | August 2025 | Allow | 38 | 1 | 0 | No | No |
| 17829158 | METHODS FOR LABELLING NUCLEIC ACIDS | May 2022 | September 2025 | Allow | 40 | 1 | 1 | No | No |
| 17824215 | METHODS AND PROBES FOR PERFORMING PCR WITH MELT ANALYSIS FOR INCREASED MULTIPLEXING | May 2022 | January 2025 | Allow | 32 | 0 | 0 | No | No |
| 17735904 | Estimating Tumor Purity From Single Samples | May 2022 | September 2024 | Allow | 29 | 1 | 0 | Yes | No |
| 17731006 | Nucleic Acid Taggants | April 2022 | February 2025 | Allow | 33 | 2 | 0 | Yes | No |
| 17728463 | METHODS FOR STANDARDIZED SEQUENCING OF NUCLEIC ACIDS AND USES THEREOF | April 2022 | July 2025 | Allow | 38 | 1 | 0 | No | No |
| 17725127 | DEVICES AND METHODS FOR LOADING OF FLUIDIC RECEPTACLES | April 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17763998 | METHOD OF PREDICTING PRODUCTION STABILITY OF CLONAL CELL LINES | March 2022 | October 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17700373 | COMPOSITIONS AND METHODS FOR MOLECULAR LABELING | March 2022 | September 2024 | Allow | 30 | 6 | 0 | No | No |
| 17698897 | PRECISION MEDICINE PORTAL FOR HUMAN DISEASES | March 2022 | October 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17761419 | KIT AND METHOD OF USING KIT | March 2022 | January 2026 | Abandon | 46 | 1 | 1 | No | No |
| 17641518 | INSTRUMENT AND METHOD FOR EXTRACTING AND DETECTING NUCLEIC ACIDS | March 2022 | January 2026 | Allow | 47 | 1 | 0 | No | No |
| 17286421 | PHASE-ISOLATED WATER-IN-OIL TRANSPARENT MACROEMULSION AND APPLICATION THEREOF | March 2022 | September 2025 | Abandon | 53 | 1 | 0 | No | No |
| 17679310 | COMPOSITIONS AND METHODS FOR MOLECULAR LABELING | February 2022 | September 2025 | Allow | 43 | 8 | 0 | Yes | No |
| 17636591 | METHOD FOR AMPLIFYING NUCLEOTIDE SEQUENCE AND SEQUENCE DETERMINATION | February 2022 | November 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17651225 | NANOPORE-BASED POLYMER ANALYSIS WITH MUTUALLY-QUENCHING FLUORESCENT LABELS | February 2022 | November 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17630004 | POLYNUCLEOTIDES FOR THE AMPLIFICATION AND DETECTION OF NEISSERIA GONORRHOEAE | January 2022 | April 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17575914 | DETECTING NUCLEIC ACID | January 2022 | December 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17568077 | METHODS AND COMPOSITIONS FOR STABILIZING NUCLEIC ACID-NUCLEOTIDE-POLYMERASE COMPLEXES | January 2022 | May 2025 | Allow | 40 | 1 | 0 | No | No |
| 17562346 | Small RNA Capture, Detection and Quantification | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17547920 | DEVICES, SYSTEMS AND METHODS FOR BIOMARKER ANALYSIS | December 2021 | December 2023 | Abandon | 24 | 4 | 0 | Yes | No |
| 17531270 | SYSTEMS AND PROCESSES FOR DISTINGUISHING PATHOGENIC AND NON-PATHOGENIC SEQUENCES FROM SPECIMENS | November 2021 | April 2025 | Allow | 41 | 1 | 0 | No | No |
| 17529082 | COMPOSITIONS AND METHODS FOR MOLECULAR LABELING | November 2021 | June 2024 | Allow | 31 | 5 | 0 | No | No |
| 17599423 | Shape-Responsive Nanostructures | September 2021 | January 2025 | Allow | 40 | 1 | 0 | No | No |
| 17470828 | PCR TUBE, APPARATUS FOR PCR INCLUDING THE SAME AND PCR METHOD USING THE SAME | September 2021 | November 2024 | Allow | 38 | 1 | 0 | No | No |
| 17458995 | NUCLEIC ACID ANALYSIS BY JOINING BARCODED POLYNUCLEOTIDE PROBES | August 2021 | January 2025 | Allow | 41 | 1 | 0 | No | No |
| 17434293 | AN IMPROVED METHOD OF PREPARING CLINICAL SAMPLES FOR NUCLEIC ACID AMPLIFICATION | August 2021 | May 2025 | Allow | 44 | 1 | 0 | No | No |
| 17397280 | UNIVERSAL SANGER SEQUENCING FROM NEXT-GEN SEQUENCING AMPLICONS | August 2021 | November 2024 | Allow | 39 | 2 | 0 | No | No |
| 17397320 | METHOD OF CHARACTERIZING A TARGET RIBONUCLEIC ACID (RNA) COMPRISING FORMING A COMPLEMENTARY POLYNUCLEOTIDE WHICH MOVES THROUGH A TRANSMEMBRANE PORE | August 2021 | July 2025 | Allow | 47 | 2 | 0 | No | No |
| 17427266 | MULTIPLEX PCR METHOD USING APTAMER | July 2021 | March 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17369796 | SEQUENCES FOR DETECTION AND IDENTIFICATION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) OF MREJ TYPE XXI | July 2021 | March 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17369834 | ANALYSIS OF A POLYNUCLEOTIDE VIA A NANOPORE SYSTEM | July 2021 | March 2025 | Allow | 44 | 1 | 0 | No | No |
| 17356402 | METHOD FOR DETECTING CHIKUNGUNYA VIRUS | June 2021 | February 2025 | Allow | 44 | 3 | 0 | Yes | No |
| 17346077 | NUCLEIC ACID ASSAYS USING CLICK CHEMISTRY BIOCONJUGATION | June 2021 | September 2024 | Allow | 60 | 1 | 0 | No | No |
| 17336055 | OLIGONUCLEOTIDES AND BEADS FOR 5 PRIME GENE EXPRESSION ASSAY | June 2021 | July 2024 | Allow | 38 | 1 | 1 | No | No |
| 17316416 | METHOD FOR LABEL-FREE SINGLE-MOLECULE DNA SEQUENCING AND DEVICE FOR IMPLEMENTING SAME | May 2021 | December 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17289499 | Compositions and Methods for Discriminating Infectious from Non-Infectious CNS Disorders | April 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17236889 | TERMINAL FUNCTIONALIZATION OF TARGET MOLECULES FOR SEQUENCING | April 2021 | December 2024 | Abandon | 44 | 2 | 0 | No | No |
| 17283968 | CATALYTIC BIOMOLECULE ACTIVITY RECORDING INTO DNA SEQUENCE | April 2021 | September 2024 | Allow | 42 | 1 | 0 | No | No |
| 16760185 | INTRAORAL EXAMINATION METHOD USING INFORMATION ON BACTERIAL GROUP RELATED TO CLINICAL INDEXES | April 2021 | March 2026 | Abandon | 60 | 4 | 0 | Yes | No |
| 17264427 | METHOD FOR THE QUALITY CONTROL OF SEED LOTS | January 2021 | March 2026 | Abandon | 60 | 4 | 0 | No | No |
| 17126693 | METHOD OF NONSPECIFIC TARGET CAPTURE OF NUCLEIC ACIDS | December 2020 | September 2024 | Allow | 45 | 4 | 1 | No | No |
| 17120518 | DETECTING CHOLANGIOCARCINOMA | December 2020 | August 2024 | Allow | 44 | 4 | 0 | Yes | No |
| 16953547 | DETERMINATION OF CELLS USING AMPLIFICATION | November 2020 | October 2025 | Abandon | 59 | 6 | 0 | No | No |
| 17070190 | Methods for Making Nucleotide Probes for Sequencing and Synthesis | October 2020 | August 2024 | Allow | 46 | 2 | 1 | No | No |
| 17046552 | DNA-TAGGED METHANOL RESPONSIVE POLYMER FOR SINGLE-STRANDED NUCLEIC ACID PRODUCTION | October 2020 | December 2023 | Allow | 38 | 3 | 0 | No | No |
| 17036401 | DETERMINISTIC BARCODING FOR SPATIAL OMICS SEQUENCING | September 2020 | July 2024 | Allow | 46 | 3 | 1 | No | No |
| 16979481 | METHODS OF SEQUENCING NUCLEIC ACIDS AND ERROR CORRECTION OF SEQUENCE READS | September 2020 | August 2024 | Allow | 47 | 4 | 0 | No | No |
| 16970318 | METHODS AND COMPOSITIONS FOR RICKETTSIACEAE DETECTION | August 2020 | April 2025 | Abandon | 56 | 3 | 1 | No | No |
| 16964386 | HYBRIDIZATION CHAIN REACTION-BASED METHOD FOR AMPLIFYING IMMUNOSIGNALS | July 2020 | November 2024 | Allow | 52 | 3 | 0 | No | No |
| 16869481 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID DETECTION | May 2020 | May 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16628828 | HIGH-COVERAGE AND ULTRA-ACCURATE IMMUNE REPERTOIRE SEQUENCING USING MOLECULAR IDENTIFIERS | January 2020 | February 2025 | Abandon | 60 | 4 | 1 | Yes | No |
| 16611190 | METHOD AND APPARATUS FOR CAPTURING HIGH-PURITY NUCLEOTIDES | November 2019 | July 2025 | Allow | 60 | 6 | 0 | Yes | No |
| 16608014 | DIRECT NUCLEIC ACID ANALYSIS OF ENVIRONMENTAL AND BIOLOGICAL SAMPLES | October 2019 | August 2025 | Abandon | 60 | 7 | 0 | No | No |
| 16596587 | SIMULTANEOUS QUANTIFICATION OF A PLURALITY OF PROTEINS IN A USER-DEFINED REGION OF A CROSS-SECTIONED TISSUE | October 2019 | June 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 16544727 | METHODS FOR QUANTIFYING EFFICIENCY OF NUCLEIC ACID EXTRACTION AND DETECTION | August 2019 | September 2025 | Allow | 60 | 8 | 1 | Yes | No |
| 16444619 | METHODS FOR NON-INVASIVE PRENATAL PLOIDY CALLING | June 2019 | August 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16347387 | METHOD FOR DETERMINING A HEAD AND NECK SQUAMOUS CELL CARCINOMA | May 2019 | March 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 15785680 | Low Sequence Bias Single-Stranded DNA Ligation | October 2017 | December 2019 | Allow | 26 | 1 | 0 | No | No |
| 15587944 | DETECTING NUCLEIC ACID | May 2017 | December 2019 | Allow | 31 | 1 | 0 | No | No |
| 15442864 | DNA SEQUENCING AND PROCESSING | February 2017 | August 2019 | Allow | 30 | 0 | 0 | Yes | No |
| 15285421 | Compositions And Methods For Immunodominant Antigens | October 2016 | August 2018 | Allow | 23 | 0 | 0 | No | No |
| 15271269 | REAL-TIME PCR POINT MUTATION ASSAYS FOR DETECTING HIV - 1 RESISTANCE TO ANTIVIRAL DRUGS | September 2016 | September 2019 | Allow | 35 | 2 | 1 | Yes | No |
| 15056475 | COMBINED THERMAL DEVICES FOR THERMAL CYCLING | February 2016 | November 2018 | Allow | 33 | 1 | 0 | No | No |
| 14931716 | EXOSOMES AND MICROVESICLES IN INTESTINAL LUMINAL FLUIDS AND STOOL AND USE OF SAME FOR THE ASSESSMENT OF INFLAMMATORY BOWEL DISEASE | November 2015 | December 2018 | Allow | 37 | 1 | 1 | No | No |
| 14765782 | METHOD FOR MEASURING BONE LOSS RATE | August 2015 | February 2018 | Allow | 30 | 2 | 0 | No | No |
| 14702628 | METHODS AND GENOTYPING PANELS FOR DETECTING ALLELES, GENOMES, AND TRANSCRIPTOMES | May 2015 | January 2018 | Allow | 32 | 0 | 0 | No | No |
| 14395239 | METHODS FOR REAL-TIME SAMPLING OF REACTION PRODUCTS | October 2014 | October 2017 | Allow | 36 | 1 | 1 | No | No |
| 14512694 | Digital Amplification | October 2014 | January 2018 | Allow | 39 | 1 | 1 | No | No |
| 14472155 | SPERM CELL SEPARATION METHODS AND COMPOSITIONS CONTAINING APTAMERS OR NUCLEIC ACID SEQUENCES FOR USE THEREIN | August 2014 | June 2016 | Allow | 22 | 1 | 0 | No | No |
| 14036527 | DOUBLE STRANDED LINEAR NUCLEIC ACID PROBE | September 2013 | March 2016 | Allow | 30 | 1 | 0 | Yes | No |
| 13748380 | DETECTION, IDENTIFICATION AND DIFFERENTIATION OF EUBACTERIAL TAXA USING A HYBRIDIZATION ASSAY | January 2013 | October 2015 | Allow | 33 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WOOLWINE, SAMUEL C.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 37.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner WOOLWINE, SAMUEL C works in Art Unit 1681 and has examined 171 patent applications in our dataset. With an allowance rate of 88.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 43 months.
Examiner WOOLWINE, SAMUEL C's allowance rate of 88.9% places them in the 70% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by WOOLWINE, SAMUEL C receive 2.56 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by WOOLWINE, SAMUEL C is 43 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +4.5% benefit to allowance rate for applications examined by WOOLWINE, SAMUEL C. This interview benefit is in the 29% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 25.6% of applications are subsequently allowed. This success rate is in the 41% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 45.8% of cases where such amendments are filed. This entry rate is in the 70% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 93.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 83.3% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 22.2% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 15.8% of allowed cases (in the 92% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.